Figure 2

Suppressing the JAK/STAT3 pathway with a small molecule inhibitor of JAK (JAKi) enhanced the anti-tumor activity of gefitinib in human ovarian cancer cells. (A) SKOV3 cells were treated with JAKi (AZD1480) or gefitinib alone or in combination at various concentrations in a fixed molar ratio 1:1. Cell viability was determined 72 h later. (B) SKOV3 cells were treated with JAKi (5 μM) or gefitinb (5 μM) either as single agent or in combination. Cell viability was determined 24 h, 48 h and 72 h later. (C) SKOV3 cells were incubated with increasing amounts of gefitinib in the presence of a fixed concentration of JAKi. Cell viability was determined 72 h later. OVCAR8 (D), MDAH2774 (E) and OVCAR 3 cells (F) were treated with gefitinib or JAKi either alone or in combination. Cell viability was determined 72 h later. Results are representative of 2–5 preparations.